Format

Send to

Choose Destination
Pulm Circ. 2018 Jul-Sep;8(3):2045894018793580. doi: 10.1177/2045894018793580.

Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

Author information

1
1 Division of Pediatric Cardiology, Department of Pediatrics, Medical University of Graz, Austria.
2
2 Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Germany.

Abstract

We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding selexipag as a third oral PAH-targeted agent in children not responding well to dual PAH therapy.

KEYWORDS:

Pediatric; prostacyclin receptor agonist; pulmonary arterial hypertension; selexipag

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center